|  | Placebo | ARB |
---|---|---|---|
 |  | (n = 40) | (n = 41) |
Demographics | |||
 Age | years | 62 ± 14 | 61 ± 16 |
 Gender (males) | n (%) | 25 (63) | 30 (73) |
 Body weight | kg | 81 ± 17 | 79 ± 17 |
 Body mass index | kg/m2 | 27 ± 5 | 26 ± 5 |
 Diabetes | n (%) | 12 (30) | 13 (32) |
 Heart disease | n (%) | 17 (43) | 15 (37) |
 Ischemic heart disease | n (%) | 9 (23) | 8 (20) |
 Charlson co-morbidity index |  | 3.5 ± 1.6 | 3.8 ± 1.9 |
 LV mass index | g/m2 | 126 ± 36 | 126 ± 33 |
 LV EF | % | 60 ± 9 | 62 ± 9 |
Cardiac medications | |||
 Aspirin treatment | n (%) | 21 (51) | 16 (39) |
 Antiplatelet (non-aspirin) drugs | n (%) | 3 (7) | 3 (7) |
 Statin treatment | n (%) | 21 (51) | 15 (37) |
 Nitrate medication | n (%) | 6 (14) | 4 (10) |
BP and BP-medication | |||
 Baseline systolic BP (preHD) | mmHg | 145 ± 19 | 148 ± 21 |
 Baseline diastolic BP (preHD) | mmHg | 72 ± 12 | 76 ± 13 |
 12 month systolic BP (preHD) | mmHg | 136 ± 22 | 138 ± 20 |
 12 month diastolic BP (preHD) | mmHg | 68 ± 15 | 69 ± 11 |
 BP-drugs excl. Placebo/ARB | n | 2.6 ± 1.0 | 2.5 ± 0.9 |
 BP-drugs excl. Placebo/ARB | DDD | 1.8 ± 1.3 | 1.8 ± 1.2 |
Dialysis parameters | |||
 Time on dialysis | days | 141 (53–431) | 148 (54–400) |
 AV-fistula/central catheter | n (%) | 35 (88)/5 (12) | 32 (78)/9 (22) |
 Urine output | L/24 h | 1.3 ± 0.7 | 1.4 ± 0.8 |
 Glomerular filtration rate | mL/min/1.73 m2 | 4.8 ± 2.3 | 5.7 ± 3.3 |
 Frequency | times/week | 3 (2–3) | 3 (2–4) |
 HD-time | hours/week | 10 ± 2 | 11 ± 3 |
 Ultrafiltration | L | 1.2 (0–4.3) | 0.5 (0–3.8) |
 Urea reduction ratio | % | 64 ± 8 | 62 ± 9 |
 Hematocrit (EVF) |  | 0.33 ± 0.05 | 0.34 ± 0.04 |